Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 11 October 2025 - 18 October 2025

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81 Stockanalysis Stockanalysis. That rally marked a new 2025 high for the biotech…
18 October 2025
····
XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook

XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook

XORTX Stock Price Skyrockets on Acquisition News Shares of XORTX Therapeutics Inc. (NASDAQ: XRTX) surged on October 17, 2025 after the nano-cap biotech announced a strategic acquisition in its core therapeutic area. The stock rocketed up immediately following the morning press release, spiking up to 40% in early trading. By midday, XRTX was changing hands at just over $1.20 per…
17 October 2025
···
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Menopause Launch Sparks Surge in HIMS Stock Hims & Hers’ expansion into menopause care was greeted with enthusiasm in the market. On October 15, the San Francisco–based telehealth provider announced it is now offering affordable treatment plans for women in perimenopause and menopause via its Hers platform Businesswire Businesswire. The move adds a new specialty to Hers, which already serves…
17 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price skyrocketed on Friday, Oct. 17, after the company unveiled a major partnership and funding news. In pre-market trade, RANI jumped about 150% and continued to rally after the market open Tipranks. The stock, which had closed at just $0.47 the prior day, briefly hit approximately $1.37 per share –…
17 October 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

LLY Stock Skyrockets, Then Dips on Pricing Jitters Eli Lilly’s stock has been on a tear in 2025, powered by optimism around its new drug innovations. Shares surged dramatically at the start of October – leaping from about $726 at the end of September to as high as $832 by October 1 ts2.tech. This double-digit jump in just days far…
17 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from…
17 October 2025
···
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

PRAX Stock Soars on Historic Trial Win Praxis Precision Medicines stock has seen a record-breaking spike in recent days after announcing landmark clinical trial results. On October 16, PRAX shares closed at $162.71, up about 183% in a single session ts2.tech ts2.tech. The stock, which had closed at $57.35 the day prior, more than tripled to reach new 52-week highs…
17 October 2025
····
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX Stock Climbs on Arbli Launch Pills and a daily pill organizer: Arbli’s liquid formulation helps patients (especially children/elderly) who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwide Globenewswire.…
16 October 2025
····
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Stock Price Rollercoaster in 2025 Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On September 19, shares opened at a mere $0.08 but skyrocketed 98% by day’s end to $0.16, then jumped another 30%…
16 October 2025
····
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Figure: Hims & Hers markets a broad telehealth platform for men’s and women’s health ts2.tech. Its stock has surged with the boom in telehealth and weight-loss treatments. Women’s Health Expansion Sparks Rally On Oct. 15, Hims & Hers stunned the market by launching a dedicated menopause/perimenopause care program on its “Hers” telehealth platform. The company said the new service would…
16 October 2025
··
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025 Marketbeat. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50 Investing. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into…
11 October 2025
····
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

Company Background AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicines Marketbeat Astrazeneca. Headquartered in Cambridge, UK, it maintains primary listings on the London Stock Exchange and Nasdaq Stockholm, with secondary ADR trading in the U.S. Astrazeneca. The company was formed in 1999 by merging Sweden’s Astra AB and the UK’s Zeneca.…
11 October 2025
····
1 … 41 42 43 44 45

Stock Market Today

  • Four Seasons Education (NYSE:FEDU) Shares Tumble 30% Amid Mixed Growth Signals
    January 22, 2026, 6:48 AM EST. Shares of Four Seasons Education (Cayman) Inc. (NYSE:FEDU) have plunged 30% in the past month, continuing a difficult 27% decline over the last year. Despite a seemingly attractive price-to-earnings (P/E) ratio of 13.5x, below the U.S. market average of roughly 20x, the company's uneven earnings growth raises concerns. After a striking 323% earnings per share increase last year, the firm showed no growth across the past three years, suggesting inconsistent performance. This lag behind the broader market's projected 16% expansion likely explains the low P/E and wary investor sentiment. The sharp stock drop reflects caution about the company's future growth prospects, signaling that its current valuation more so captures investor apprehension than undervaluation.
Go toTop